By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Altimmune, Inc. 

19 Firstfield Road

Gaithersburg  Maryland  20878   U.S.A.
Phone: 240-654-1450 Fax: n/a


Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.




CEO: Bill Enright, MBA

Chief Scientific Officer: Scot Roberts, PhD

CFO: Elizabeth A. Czerepak

Chief Technology Officer: Bertrand Georges, PhD

Key Statistics

Ownership: Private

Web Site: Altimmune

Company News
Altimmune Expands to New HQ With Plans for New Jobs 8/23/2017 6:31:25 AM
Altimmune Closes Series B Preferred Stock Offering 8/22/2017 10:24:45 AM
Altimmune Submits Investigational New Drug Application For Nasovax In Preparation For Phase II Trial 8/21/2017 8:59:33 AM
Altimmune Announces $14.7 Million Series B Preferred Stock Offering 8/17/2017 10:13:34 AM
Altimmune To Announce Second Quarter 2017 Financial Results On August 10 7/31/2017 1:14:15 PM
Altimmune Promotes Dr. Sybil Tasker To Chief Medical Officer 5/16/2017 10:45:51 AM
Altimmune Completes Merger With PharmAthene, Inc. (PIP) Creating Immunotherapeutics Company Targeting Infectious Diseases 5/5/2017 11:24:47 AM
PharmAthene, Inc. (PIP) Announces Record Date And Meeting Date For Special Meeting Of Stockholders Regarding Proposed Merger Transaction With Altimmune 3/13/2017 9:10:05 AM
PharmAthene, Inc. (PIP) Release: Company And Altimmune Announce Merger To Create Immunotherapeutics Company Targeting Infectious Diseases 1/19/2017 7:58:32 AM
Altimmune Receives BARDA Contract Of Up To $120.2 Million To Fund Clinical Development Of First-In-Class Anthrax Vaccine Candidate Nasoshield 8/2/2016 10:32:15 AM